Market closed
Catalyst Pharmaceuticals/$CPRX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Ticker
$CPRX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
167
Website
CPRX Metrics
BasicAdvanced
$2.6B
Market cap
18.14
P/E ratio
$1.18
EPS
0.75
Beta
-
Dividend rate
Price and volume
Market cap
$2.6B
Beta
0.75
52-week high
$23.37
52-week low
$13.12
Average daily volume
1M
Financial strength
Current ratio
5.114
Quick ratio
4.75
Long term debt to equity
0.437
Total debt to equity
0.497
Management effectiveness
Return on assets (TTM)
18.35%
Return on equity (TTM)
28.29%
Valuation
Price to earnings (TTM)
18.139
Price to revenue (TTM)
5.347
Price to book
3.86
Price to tangible book (TTM)
5.15
Price to free cash flow (TTM)
13.252
Growth
Revenue change (TTM)
32.17%
Earnings per share change (TTM)
114.68%
3-year revenue growth (CAGR)
51.08%
3-year earnings per share growth (CAGR)
44.65%
What the Analysts think about CPRX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Catalyst Pharmaceuticals stock.
CPRX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CPRX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CPRX News
AllArticlesVideos
Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List
GlobeNewsWire·3 weeks ago
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewsWire·4 weeks ago
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Catalyst Pharmaceuticals stock?
Catalyst Pharmaceuticals (CPRX) has a market cap of $2.6B as of December 15, 2024.
What is the P/E ratio for Catalyst Pharmaceuticals stock?
The price to earnings (P/E) ratio for Catalyst Pharmaceuticals (CPRX) stock is 18.14 as of December 15, 2024.
Does Catalyst Pharmaceuticals stock pay dividends?
No, Catalyst Pharmaceuticals (CPRX) stock does not pay dividends to its shareholders as of December 15, 2024.
When is the next Catalyst Pharmaceuticals dividend payment date?
Catalyst Pharmaceuticals (CPRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals (CPRX) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.